Drug Trial Radar · NCT04604652
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
May 27, 2021
Primary completion
May 31, 2022
Study completion May 31, 2022
Sponsor
- Lead sponsor
- HighTide Therapeutics (Hong Kong) LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this open-label study is to evaluate the safety and tolerability of HDT1801 (BUDCA) over 12 weeks in adult subjects with PBC who have an inadequate response to standard therapy. Inadequate response is defined as persistently elevated serum alkaline phosphatase at greater than or equal to1.5 times the upper limits of normal for the testing lab in spite of having been on adequate doses of standard therapy with UDCA (ursodeoxycholic acid) at 13-15 mg/kg for at least 6 months.
Conditions
- Primary Biliary Cholangitis
- Primary Biliary Cirrhosis
- Cholangitis
- Cholestasis
- Biliary Tract Diseases
- Bile Duct Stricture
Interventions
HTD1801 (BUDCA)Drug
HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Alkaline Phosphatase (ALP) at Week 12 Compared to BaselineTime frame: Baseline to Week 12
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
University of Miami Schiff Center for Liver Disease
Miami, Florida
Piedmont Healthcare
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Henry Ford Health Services
Detroit, Michigan
St. Louis University
St Louis, Missouri
Northshore University Hospital
Manhasset, New York
University GI
Providence, Rhode Island
Baylor Research Institute
Dallas, Texas
The Texas Liver Institute
San Antonio, Texas
Liver Institute of Virginia
Newport News, Virginia
Bon Secours Liver Institute of Richmond
Richmond, Virginia
Liver Institute Northwest
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.